Sugi Predict

Sugi Predict / Compounds / SCHEMBL23293454

SCHEMBL23293454

SCHEMBL23293454

Cn1c(=O)c([N+](=O)[O-])c(N2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c2nc(OC(N)=O)ccc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 6/20 0.69
▸ DGKZ Q13574 5/20 0.69
▸ DGKI O75912 3/20 0.69
▸ DGKG P49619 2/20 0.69
▸ DGKB Q9Y6T7 2/20 0.69
▸ DGKK Q5KSL6 1/20 0.69
▸ MGLL Q99685 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ GPX4 P36969 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ BRAF P15056 1/20 0.34
▸ RAB9A P51151 1/20 0.33
▸ PAX8 Q06710 1/20 0.33
▸ HTR1A P08908 2/20 0.33
▸ CHRM1 P11229 2/20 0.33
▸ DRD2 P14416 2/20 0.33
▸ ADRA1D P25100 2/20 0.33
▸ ADRA1A P35348 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30616462 0.86 DGKA (0.76) DGKADGKZDGKIDGKGDGKB
SCHEMBL23293182 0.86 DGKA (0.76) DGKADGKZDGKIDGKGDGKB
SCHEMBL29898584 0.84 DGKA (0.76) DGKADGKZDGKIDGKGDGKB
SCHEMBL23293369 0.84 DGKA (0.76) DGKADGKZDGKIDGKGDGKB
SCHEMBL23293485 0.83 DGKA (0.69) DGKADGKZDGKIDGKGDGKB
SCHEMBL21830991 0.82 DGKA (1.00) DGKADGKZDGKIDGKGDGKB
SCHEMBL29654799 0.82 DGKA (1.00) DGKADGKZDGKIDGKGDGKB
SCHEMBL23802314 0.81 DGKA (0.64) DGKADGKZDGKIDGKGDGKB
SCHEMBL30616390 0.81 DGKA (0.64) DGKADGKZDGKIDGKGDGKB
SCHEMBL23802622 0.81 DGKA (0.61) DGKADGKZDGKIDGKGDGKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866430-B2 Naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-09 — — US disclosed
CN-112585139-B Naphthyridinone compounds as T cell activators 百时美施贵宝公司 2023-12-01 — — CN disclosed
EP-3814347-B1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-03 — — EP disclosed
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2021-09-09 — — US disclosed
EP-3814347-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2021-05-05 — — EP disclosed
CN-112585139-A Nalidinone compounds as T cell activators 百时美施贵宝公司 2021-03-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866430-B2 Naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG DGKA 2/4885DGKZ 1/4885DGKI 6/4885
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG DGKA 2/4885DGKZ 1/4885DGKI 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.